Drugs / G100
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02387125 | Feb 2015 → Mar 2019 | melanoma, non-small cell lung carcinoma, ovarian cancer, sarcoma | Immune Design | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02501473 | Feb 2016 → Aug 2019 | follicular lymphoma | Immune Design | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT02406781 | Jun 2015 → Nov 2020 | sarcoma | Institut Bergonié | Completed | Mixed |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | G100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02406781 ↗ |
| Action | Activate | “toll-like receptor-4 (TLR-4) agonist” NCT02387125 ↗ |
| Modality | Small molecule | “a potent synthetic small molecule” NCT02387125 ↗ |
| Route | Other | “intratumoral G100” NCT02387125 ↗ |
| Target | TLR4 | “toll-like receptor-4 (TLR-4) agonist” NCT02387125 ↗ |